Outcomes of conversion surgery following chemotherapy for initially unresectable metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study in Taiwan.

ABSTRACT:

Purpose

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a high mortality rate. For patients with metastatic PDAC (mPDAC) initially deemed unresectable, systemic chemotherapy followed by conversion surgery may offer an improvement in survival. This study aimed to compare survival between mPDAC patients undergoing conversion surgery versus chemotherapy alone, and identify factors associated with recurrence following conversion surgery.

Methods

We conducted a retrospective cohort study of patients with mPDAC treated with systemic chemotherapy at National Cheng Kung University Hospital, Taiwan, between September 2020 and January 2023. Patients who subsequently underwent conversion surgery were analyzed to identify factors associated with recurrence. Clinicop

SUBMITTER: Su PJ 

PROVIDER: S-EPMC12575905 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature